These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1021 related items for PubMed ID: 30258889

  • 1. Temozolomide resistance in glioblastoma multiforme.
    Lee SY.
    Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
    [Abstract] [Full Text] [Related]

  • 2. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J, Stevens MF, Bradshaw TD.
    Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
    [Abstract] [Full Text] [Related]

  • 3. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
    Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW.
    Cancer Res; 2011 Mar 15; 71(6):2308-17. PubMed ID: 21406402
    [Abstract] [Full Text] [Related]

  • 4. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
    Yuan AL, Meode M, Tan M, Maxwell L, Bering EA, Pedersen H, Willms J, Liao J, Black S, Cairncross JG, Blough MD.
    J Neurooncol; 2020 Jul 15; 148(3):463-472. PubMed ID: 32562246
    [Abstract] [Full Text] [Related]

  • 5. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
    Zhang J, Stevens MF, Hummersone M, Madhusudan S, Laughton CA, Bradshaw TD.
    Oncology; 2011 Jul 15; 80(3-4):195-207. PubMed ID: 21720182
    [Abstract] [Full Text] [Related]

  • 6. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway.
    Tang Q, Cao H, Tong N, Liu Y, Wang W, Zou Y, Xu L, Zeng Z, Xu W, Yin Z, Ma W, Wang Q.
    Phytomedicine; 2022 May 15; 99():154016. PubMed ID: 35278900
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, Bringman LR, Wells CD, Murray ME, Sarkaria JN, Gelbert LM, Jones DR, Cohen-Gadol AA, Mayo LD, Shannon HE, Pollok KE.
    J Neurosurg; 2017 Feb 15; 126(2):446-459. PubMed ID: 27177180
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP.
    Clin Cancer Res; 2020 Apr 01; 26(7):1690-1699. PubMed ID: 31900275
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells.
    Wang X, Jia L, Jin X, Liu Q, Cao W, Gao X, Yang M, Sun B.
    Oncol Lett; 2015 Jun 01; 9(6):2586-2590. PubMed ID: 26137111
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
    Vlachostergios PJ, Hatzidaki E, Befani CD, Liakos P, Papandreou CN.
    Invest New Drugs; 2013 Oct 01; 31(5):1169-81. PubMed ID: 23645448
    [Abstract] [Full Text] [Related]

  • 18. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.
    Ye L, Gu L, Wang Y, Xing H, Li P, Guo X, Wang Y, Ma W.
    CNS Neurosci Ther; 2024 Mar 01; 30(3):e14649. PubMed ID: 38448295
    [Abstract] [Full Text] [Related]

  • 19. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH, Chang TY, Lin WC, Wei KC, Shin JW.
    Sci Rep; 2017 Aug 18; 7(1):8814. PubMed ID: 28821714
    [Abstract] [Full Text] [Related]

  • 20. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
    Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F.
    Clin Transl Oncol; 2018 Apr 18; 20(4):508-516. PubMed ID: 28825189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.